Stephen R. Davis has been strategic with his holdings in Acadia Pharmaceuticals. Recently, he has increased his investment in the company, owning a large number of restricted stock units (RSUs) which greatly contribute to his overall wealth. His vested stock...

Stock Sold

$33.20M

ACAD

$33.20M

901,217 shares

What if they kept their stock?

If Stephen R. Davis didn't sell their stock, today they would have:
Extra ACAD901,217 shares worth $15.83M.
This is -52.31% and $17.37M less than what they got when they sold the stock.

Recent Insider Trades

ACAD

62,115 shares

ACAD

Aug 16, 2024

Received

ACAD

$193.57K

ACAD at $16.94/share

May 1, 2024

Sale

ACAD

$474.88K

ACAD at $17.87/share

Apr 5, 2024

Sale

ACAD

$317.08K

ACAD at $17.90/share

Mar 25, 2024

Sale

ACAD

34,666 shares

ACAD

Mar 25, 2024

Received

ACAD

$137.58K

ACAD at $24.67/share

Feb 23, 2024

Sale

ACAD

$111.81K

ACAD at $29.96/share

Jan 6, 2024

Sale

ACAD

$1.13M

ACAD at $21.96/share

Oct 5, 2023

Sale

ACAD

$3.00M

ACAD at $30.04/share

Jul 14, 2023

Sale

ACAD

$1.38M

ACAD at $25.05/share

Jul 11, 2023

Sale

Stephen R. Davis

CEO of Acadia Pharmaceuticals

A

View Compensation History

2023 Total Compensation

$5.64M

Salary

$862.12K

Bonus

$886.18K

Stock

$3.87M

Other

$30.57K